Single-nucleus transcriptomics identifies SPON1 as a candidate mediator of the anti-fibrotic effect of Abelmoschus manihot (L.) in diabetic kidney disease.
文献摘要
Objectives This study elucidated the cell-type-specific mechanisms and molecular targets underlying the anti-fibrotic effects of Abelmoschus manihot (AM) extract in diabetic kidney disease (DKD). We focused on identifying fibrosis-associated regulators using single-nucleus RNA sequencing (snRNA-seq) and validating them experimentally. Methods DKD was induced in C57BL/6J mice by a high-fat diet and streptozotocin. Mice received oral AM extract (2.0 g/kg/day) for 14 weeks. We performed snRNA-seq on control, DKD, and AM-treated kidneys, utilizing computational tools to infer intercellular communication. Validation was conducted using quantitative real-time polymerase chain reaction (qRT-PCR), immunohistochemistry, western blotting, and confocal microscopy. In vitro , human renal proximal tubular epithelial (HK-2) cells were exposed to high glucose (HG) with or without AM treatment. Results AM significantly reduced the urinary albumin-to-creatinine ratio and ameliorated glomerular and interstitial fibrosis in DKD mice. snRNA-seq identified proximal tubular segment 1 and interstitial cell clusters as the primary responders to AM. The extract suppressed transforming growth factor-beta TGF-β/Smad-related profibrotic signaling and remodeled epithelial-stromal intercellular communication by downregulating C-X-C motif chemokine ligand (CXCL) and colony-stimulating factor (CSF) pathways. Notably, spondin 1 (SPON1), an extracellular matrix-associated matricellular protein, was among the most significantly downregulated genes. Consistent with these findings, SPON1 expression was markedly reduced in both DKD kidneys and HG-injured HK-2 cells following AM administration. Conclusions AM attenuates diabetic renal fibrosis by reducing SPON1 expression, suppressing profibrotic signaling, and remodeling epithelial-stromal crosstalk. These findings provide cell-type-resolved insights into AM's renoprotective mechanisms and highlight SPON1 as a candidate molecular target in DKD.